Skip to main content

Table 1 Patient Baseline and Demographic Characteristics

From: Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study

Baseline and demographic characteristics

All patients (n = 1003)

Age at index date, years, mean (SD)

39.7 (12.4)

Sex, n (%)

 Female

760 (75.8)

 Male

241 (24.0)

 Other

2 (0.2)

Race, n (%)

 White

782 (78.0)

 Black or African American

137 (13.7)

 Asian

56 (5.6)

 Native American or American Indian

7 (0.7)

 Other

20 (2.0)

 Unknown

1 (0.1)

Migraine diagnosis, n (%)

 CM

587 (58.5)

 EM

416 (41.5)

Duration of follow-up (months), mean (SD)

7.1 (4.4)

Time from date of diagnosis to index date (years), mean (SD)

6.6 (8.5)

Number of prior treatment failures, n (%)

 0

60 (6.0)

 1

111 (11.1)

  ≥ 2

832 (82.9)

Baseline MMD, mean (SD)

12.7 (6.4)

Baseline MHD, mean (SD)

14.0 (8.0)

Baseline HIT-6 score, mean (SD)

60.0 (8.9)

Baseline MIDAS score, mean (SD)

28.7 (28.5)

Comorbid conditions at baseline, n (%)a

 Insomnia

196 (19.5)

 Allergies

158 (15.8)

 Neck pain

155 (15.5)

 Hypertension

143 (14.3)

 Back pain

138 (13.8)

 Obesity

137 (13.7)

 MDD

134 (13.4)

 GAD

120 (12.0)

 Chronic pain

111 (11.1)

 Asthma

101 (10.1)

 Fibromyalgia

96 (9.6)

 High cholesterol

94 (9.4)

 Gastroesophageal reflux

80 (8.0)

 Other anxiety (non-GAD)

60 (6.0)

 Sinusitis

52 (5.2)

  1. CM Chronic migraine, EM Episodic migraine, SD Standard deviation, MMD Monthly migraine days, MHD Monthly headache days, HIT-6 6-item Headache Impact Test, MIDAS Migraine Disability Assessment, MDD Major depressive disorder, GAD Generalized anxiety disorder
  2. aReported by ≥ 5% of patients